---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-310611"
form_type: "8-K"
ticker: "MIRM"
cik: "0001759425"
company_name: "Mirum Pharmaceuticals, Inc."
filed_at: "2025-12-08T23:59:59+00:00"
generated_at: "2026-05-16T14:01:08.772720+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# Mirum Pharmaceuticals to Acquire Bluejay Therapeutics for Up to $820M

## Summary
- Mirum pays $250M cash and up to 5.2M shares (≈$370M) at closing, plus up to $200M in milestone payments for Bluejay Therapeutics.
- Acquisition adds brelovitug, a Phase 3 monoclonal antibody for chronic hepatitis D (HDV) with Breakthrough Therapy and PRIME designations.
- Mirum also raised $200M in a PIPE from investors including Morgan Stanley, Leerink, Cantor, Raymond James, and Citizens JMP.
- Top-line Phase 3 data for brelovitug expected in second half of 2026; BLA submission anticipated in first half of 2027.
- Transaction expected to close in Q1 2026, subject to HSR clearance, stockholder approval, and other customary conditions.

## SEC filing metadata
- accession: 0001193125-25-310611
- form_type: 8-K
- ticker: MIRM
- cik: 0001759425
- company_name: Mirum Pharmaceuticals, Inc.
- filed_at: 2025-12-08T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759425/000119312525310611/0001193125-25-310611-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759425/000119312525310611/d46722d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-310611
- JSON: https://secwatch.observer/filing/0001193125-25-310611.json
- Plain text: https://secwatch.observer/filing/0001193125-25-310611.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.